Palmitic Acid and Human Microvascular Function

NCT ID: NCT06683534

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn how a supplement Quercetin can affect microvascular function.

Participants will:

* give two blood draws of 5 mL each
* have a camera placed under the tongue to take pictures of blood vessels
* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microvasculature Microvascular Dysfunction Cardiovascular Diseases Cardiovascular Diseases (CVD) Microvascular Health Obesity and Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects will be randomized to receive the supplement quercetin or placebo for 30 days to determine its effect on microvascular function.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Use of oral quercetin to improve human microvascular function

Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.

Group Type EXPERIMENTAL

Quercetin (dietary supplement)

Intervention Type DIETARY_SUPPLEMENT

Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.

Placebo

A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Subjects randomized to receive placebo will be administered a standard placebo sugar pill.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quercetin (dietary supplement)

Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Subjects randomized to receive placebo will be administered a standard placebo sugar pill.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obesity (BMI\>30)
* Aged 18-40 years
* English Speaking

Exclusion Criteria

* BMI\>60
* Resting SBP ≥180 mmHg or DBP ≥ 110mmHg
* Pregnancy or breastfeeding.
* Prior history of myocardial infarction
* Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)
* Active mouth sores that affect the buccal mucosa.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical College of Wisconsin

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Julie K. Freed

Executive Vice Chair

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Froedtert Hospital

Wauwatosa, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julia A Vogt

Role: CONTACT

4149552348

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Julia Vogt

Role: primary

4149552348

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO00053081

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Watermelon on Cardiometabolic Health
NCT07006636 NOT_YET_RECRUITING NA
Quercetin in Coronary Artery By-pass Surgery
NCT04907253 ACTIVE_NOT_RECRUITING PHASE2
HYPEROXIA Responses and ROS
NCT05958303 COMPLETED NA